First-of-its-Kind stem cell trial aims to halt debilitating MS

NCT ID NCT06592703

Recruiting now Disease control Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

Summary

This is a small, early-stage study to test the safety of a new cell therapy for a severe form of multiple sclerosis (MS). Researchers will give participants three injections of donor-derived stem cells into the spinal fluid over several months. The main goal is to see if the treatment is safe, while also checking if it might slow the worsening of disability in people with primary progressive MS.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

APHP Henri Mondor
ACTIVE_NOT_RECRUITING

Créteil, France
CHU Rennes
RECRUITING

Rennes, France

Contact

Contact

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS